Abstract
Several asthma trials have been published in recent months evaluating key treatments such as long-acting beta-2 agonists (LABAs), inhaled corticosteroids (ICSs), and tiotropium (Spiriva— oehringer Ingelheim, Pfizer). Studies have questioned the recommendation to discontinue LABAs; compared the efficacy of intermittent, symptom-based ICS use with scheduled inhalations in adults with mild to moderate persistent asthma; evaluated the effects of ICS use in children on their adult height; and evaluated the role of tiotropium in the management of uncontrolled asthma.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call